Table 1– Patients’ and controls’ baseline characteristics, pulmonary function tests, and ultrasound and tissue Doppler imaging (TDI) parameters
Total patientsWithout therapyWith therapyControls
Patients n50203045
Males/females n35/1513/722/830/15
Age yrs42±841.5±8.542.25±7.9138±12
Disease duration yrs5±4.575.1±4.653.5±4.37
Heart rate beats·min−177±1277±13.3476.88±9.5576.8±10
Systolic BP mmHg123.1±16.5125.28±17.28117.14±12.2115.8±14.3
Diastolic BP mmHg78.5±12.279.72±13.1175±8.1774.8±9.1
Pulmonary function tests % pred
 FEV192.2±1994.7±15.5285.14±26.94
 FVC97.3±18.599.8±15.7690.14±24.71
 FEV1/FVC85.31±11.886.85±9.9381±16.16
 TLC87.3±12.588.15±11.4184.86±16.05
DL,CO84±17.284.65±17.5482.14±17.27
Ultrasound parameters
 Et/At1.344±0.4561.32±0.471.39±0.461.471±0.288
  Stage I1.35±0.47
  Stage II1.26±0.57
  Stage III1.24±0.47
 Eat cm·s−114.46±4.3115.16±3.7717.00±4.1516.5±3.84
  Stage I16.2±3.87
  Stage II12.85±3.29
  Stage III12.55±1.20
 Aat cm·s−118.3±4.97*19.02±4.81*19,41±4.3*13.2±3.73
  Stage I18.72±4.54
  Stage II20.75±7.14
  Stage III17.60±0.85
 Eat/Aat0.79±0.41*0.85±0.33*0.99±0.4*1.25±0.39
  Stage I0.91±0.29
  Stage II0.74±0.51
  Stage III0.72±0.10
  • Data are presented as mean±sd unless otherwise stated. BP: blood pressure; % pred: % predicted; FEV1: forced expiratory volume in 1 s; FVC: forced expiratory vital capacity; TLC: total lung capacity; DL,CO: diffusing capacity of the lung for carbon monoxide; Et: early tricuspid diastolic wave maximal velocity using classical Doppler; At: late tricuspid diastolic wave maximal velocity using classical Doppler; Eat: early tricuspid diastolic wave maximal velocity using TDI; Aat: late tricuspid diastolic wave maximal velocity using TDI. *: p<0.05.